Dr. Wendy Moore is a Professor of Internal Medicine in the Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases at the Wake Forest School of Medicine in Winston-Salem, NC. She is the Director of the Wake Forest Airways Clinical Research Center as well as the Severe Asthma Clinic at Wake Forest Baptist Health.
Dr. Moore received her medical degree from the University of Maryland School of Medicine in 1991 in her hometown of Baltimore, Maryland. She completed her Pulmonary and Critical Care subspecialty training at her alma mater where she held a joint appointment and was funded by the Veterans Administration to conduct translational research on airways specimens from patients with allergic asthma.
In 2000 the asthma research group at Maryland was recruited to establish a new Center of Excellence in Airways research at Wake Forest University. Dr. Moore was a founding member of this group and was primarily responsible for starting a new clinical research enterprise. Now twenty years later, she is the Director of the Airways Clinical Research Center with a broad portfolio of research projects in asthma, COPD and Cystic Fibrosis that are funded by NIH, nonprofit foundations and industry sponsored multicenter clinical trials.
A particular focus for Dr. Moore’s research has been the establishment of large cross-sectional and longitudinal cohorts in asthma and COPD to better understand the pathobiologic mechanisms which lead to or worsen these diseases. Wake Forest has been a member of the NIH Severe Asthma Research Program since 2001, was a clinical site for both former NHLBI asthma clinical trial networks (ACRN and Asthmanet) and is a clinical site for the PrecISE (Precision Interventions for Severe and Exacerbation-prone asthma) precision medicine in asthma network. Wake Forest is also a clinical site for the SPIROMICS COPD cohort (Subpopulations and Intermediate Outcome Measures in COPD Study), an ongoing COPD cohort. Dr. Moore is an expert in disease phenotyping and clinical trial design whose research has been influential in our current thought processes concerning how disease activity and severity is interpreted particularly in severe asthma.
